The impact of intravenous aspirin administration on platelet aspirin resistance after on-pump coronary artery bypass surgery

References

• Stein PD, Schünemann HJ, Dalen JE, Gutterman D. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: The seventh ACCP conference on Antithrombotic and Thrombolytic therapy. Chest 2004; 126((Suppl 3))600S–608S
   PubMedGoogle Scholar
• Okrainec K, Platt R, Pilote L, Eisenberg MJ. Cardiac medical therapy in patients after coronary artery bypass graft surgery: A systematic review of randomized controlled trials. J Am Coll Cardiol 2005; 45: 177–184
   PubMedGoogle Scholar
• Filion KB, Pilote L, Rahme E, Eisenberg MJ. Perioperative use of cardiac medical therapy among patients undergoing coronary artery bypass graft surgery: A systematic review. Am Heart J 2007; 154: 407–414
   PubMedGoogle Scholar
• Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: The relationships among dose, effectiveness, and side effects: The seventh ACCP conference on Antithrombotic and Thrombolytic therapy. Chest 2004; 126(Suppl 3)234S–264S
   PubMed Web of Science ®Google Scholar
• Mangano ST. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347: 1309–1307
   PubMed Web of Science ®Google Scholar
• Stein PD, Schünemann HJ, Dalen JE, Guttermann D. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts. Chest 2004; 126: 600S–608S
   PubMedGoogle Scholar
• Zimmermann N, Kienzle P, Weber AA, Winter J, Gams E, Schrör K, Hohlfeld T. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 212: 982–984
   Google Scholar
• Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schrör K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542–547
   PubMed Web of Science ®Google Scholar
• Golański J, Chłopicki S, Golański R, Gresner P, Iwaszkiewicz A, Watala C. Resistance to aspirin in patients after coronary artery bypass graftings is transient. Ther Drug Monit 2005; 27: 484–490
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Balbay Y, Caldir V, Ayez S, Guray Y, Guray U, Korkmaz S. Late saphenous vein graft occlusion in patients with coronary bypass: Possible role of aspirin resistance. Thromb Res 2005; 115: 25–29
   PubMed Web of Science ®Google Scholar
• Zimmermann N, Kurt M, Winter J, Gams E, Wenzel V, Weber AA, Hohlfeld T. Aspirin-induced platelet inhibition in patients undergoing cardiac surgery. Platelets 2007; 18: 528–534
   PubMed Web of Science ®Google Scholar
• Zimmermann N, Kurt M, Winter J, Gams E, Wenzel V, Hohlfeld T. Detection and duration of aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2008; 135: 947–948
   PubMed Web of Science ®Google Scholar
• Zimmermann N, Gams E, Hohlfeld T. Aspirin in coronary bypass surgery: New aspects of and alternatives for an old antithrombotic agent. Eur J Cardiothorac Surg 2008; 34: 93–108
   PubMed Web of Science ®Google Scholar
• Cornelissen J, Kirtland S, Lim E, Goddard M, Bellm S, Sheridan K, Large S, Vuylsteke A. Biological efficacy of low against medium dose aspirin regimen after coronary surgery: Analysis of platelet function. Thromb Haemost 2006; 95: 476–482
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606–617
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MMC, Eikenboom CJ, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593–1599
   PubMed Web of Science ®Google Scholar
• Kraskopoulos G, Brister SJ, Beattie WS, Elliot RF, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: Systematic review and meta-analysis. BMJ 2008; 336: 195–198
   PubMedGoogle Scholar
• Antiplatelet Trialist's Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infraction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106
   PubMedGoogle Scholar
• Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiplate whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18: 199–206
   PubMed Web of Science ®Google Scholar
• Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: S715–S720
   PubMed Web of Science ®Google Scholar
• Parolari A, Mussoni L, Frigerio M, Naliato M, Alamanni F, Galanti A, Fiore G, Veglia F, Biglioni P, Camera M. Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery. J Thorac Cardiovasc Surg 2005; 130: 303–308
   PubMed Web of Science ®Google Scholar
• Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, Fitzgerald DJ. Platelet response to low-dose enteritic-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46: 1258–1263
   PubMed Web of Science ®Google Scholar
• Cox D, Maree AO, Dooley R, Byrne MF, Fitzgerald DJ. Effect of enteritic coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006; 37: 3153–3158
   Google Scholar
• FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, Brash AR. Endogeneous biosynthesis of Prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676–688
   PubMed Web of Science ®Google Scholar
• Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of Thromboxane A2 and Prostacyclin. Stroke 1992; 23: 1400–1403
   PubMed Web of Science ®Google Scholar
• Hart RG, Leonard AD, Talbert RL, Pearce LA, Cornell E, Bovill E, Feinberg WM. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy 2003; 23: 579–584
   PubMed Web of Science ®Google Scholar
• Carletti C, Dell'Elba G, Manarini S, Pecce R, Di Casteinuovo A, Scorpiglione N, Feliziani V, de Gaetano G. Pharmacokinetic and pharmacodynamic differences between two low doses of aspirin may affect therapeutic outcomes. Clin Pharmackinet 2003; 42: 1059–1070
   Google Scholar
• Dippel DW, Van Kooten F, Leebeck FW, van Vliet HH, Mehicevic A, Li SS, Koudstaal PJ. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke?. Cerebrovasc Dis 2004; 17: 296–302
   PubMed Web of Science ®Google Scholar
• Lee PY, Chen WH, Hg W, Cheng X, Kwok JY, Tse HF, Lau CP. Low.dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118: 723–727
   PubMed Web of Science ®Google Scholar
• Roller E, Dorr A, Ulrich S, Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis 2002; 13: 277–281
   PubMed Web of Science ®Google Scholar
• Guthikonda S, Lev LI, Patel R, DeLao T, Bergeron AL, Dong JF, Kleiman NS. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 5: 490–496
   PubMed Web of Science ®Google Scholar
• MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573–574
   PubMed Web of Science ®Google Scholar
• Hohlfeld T, Zimmermann N, Weber AA, Jessen G, Weber H, Schrör K, Höltje HD, Ebel R. Pyrazilonone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 2008; 6: 166–173
   PubMedGoogle Scholar